Alembic Pharma Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue grew consistently over the past four quarters, showcasing strong demand for product lines.
Operating profit margins improved, reflecting better cost management strategies in manufacturing.
The company has expanded its market presence internationally, boosting sales in emerging markets.

NEGATIVES

Profit margins decreased slightly due to increased raw material costs in the latest quarter.
Revenue growth has slowed down compared to previous quarters, indicating a potential market saturation.
R&D expenses rose significantly, impacting overall profitability.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25
Revenue	1,486.15	1,594.93	1,630.57	1,516.97	1,561.73	1,647.98	1,692.75	1,769.64	1,710.72	1,910.15
Expenses	1,287.45	1,386.69	1,364.21	1,256.92	1,324.90	1,408.71	1,432.52	1,497.71	1,429.38	1,594.46
Operating Profit	198.70	208.24	266.36	260.05	236.83	239.27	260.23	271.93	281.34	315.69
Other Income	11.66	10.15	2.89	3.60	2.10	16.74	9.50	14.19	6.50	6.91
Interest	14.39	15.69	15.17	10.94	13.18	18.81	22.26	24.52	23.52	24.23
Depreciation	66.18	67.56	69.45	69.48	69.04	70.51	70.04	68.99	73.77	76.07
Profit Before Tax	129.76	134.63	184.58	182.84	157.03	180.42	177.79	191.95	190.10	223.72
Tax	9.16	-1.93	4.13	4.63	22.49	27.28	40.09	35.32	36.47	40.01
Net Profit	120.60	136.56	180.45	178.21	134.54	153.14	137.70	156.63	153.63	183.71
Eps in Rs	6.14	6.95	9.18	9.07	6.84	7.79	7.01	7.98	7.85	9.40